U.S. Markets closed

Sesen Bio, Inc. (SESN)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
0.7230-0.0219 (-2.94%)
At close: 04:00PM EST
0.7200 -0.00 (-0.41%)
After hours: 07:35PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.7449
Bid0.7226 x 1000
Ask0.7400 x 900
Day's Range0.7163 - 0.7599
52 Week Range0.6680 - 6.0400
Avg. Volume6,200,875
Market Cap144.212M
Beta (5Y Monthly)0.63
PE Ratio (TTM)N/A
EPS (TTM)-0.1470
Earnings DateMar 14, 2022 - Mar 18, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est2.25
  • Business Wire

    Sesen Bio Further Enhances Team with Key Hires

    CAMBRIDGE, Mass., January 10, 2022--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced the appointments of Minori Rosales, M.D., Ph.D. as Chief Development Officer as of January 24, 2022 and Stephanie Vigue as Director of Finance as of January 17, 2022.

  • InvestorPlace

    6 of the Best Penny Stocks Under $1 to Buy Now for 2022

    Put simply, 2021 was a great year to trade penny stocks under $1 per share — largely thanks to the Reddit meme stock phenomenon. Many may have believed elevated retail interest in day trading would cool with the recovery from the pandemic. But as we’ve seen over the past few months, that has hardly been the case. Granted, finding success in penny stocks may prove more difficult in 2022. In fact, you could argue it already is. Market participants have started to embrace a more “risk off” mindset

  • Motley Fool

    Why Sesen Bio Stock Got Slammed Today

    The biotech, which concentrates on developing treatments for cancer, saw its share price dive by nearly 18% on the day. In August, the company's Biologics License Application (BLA) was rejected by the Food and Drug Administration (FDA). In its press release published just after the meeting, which Sesen Bio characterized as "productive," the company wrote that it now "believes it has greater clarity regarding the requirements for resubmission of the BLA and the trial design."